Market Debut: Influx Healthtech Lists with 38% Premium
Influx Healthtech made a striking debut on the NSE Emerge platform on June 25, with its shares listing at ₹132.50 apiece.
- IPO Price: ₹96 per share
- Listing Price: ₹132.50
- Listing Gain: Over 38% premium on the issue price
The premium was significantly higher than grey market expectations, which had pegged the stock around ₹116, implying a 21% gain before listing.
Main News: Influx Healthtech's IPO Sees Exceptional Response
Influx Healthtech's SME IPO witnessed robust investor enthusiasm.
- Subscription Level: 187.32 times
- Bidding Period: June 18 to June 20
- Grey Market Premium (Pre-Listing): ₹116
This surge in interest highlights the market's current appetite for healthcare and tech-based SME offerings.
Company Details: Healthcare Focused Influx Healthtech
Influx Healthtech, headquartered in Mumbai, operates primarily in the healthcare sector. The company focuses on developing and distributing:
- Nutraceutical products
- Veterinary food solutions
- Homecare and cosmetic products
The strong debut reflects growing investor interest in niche, healthcare-oriented companies that tap the SME segment.
Financial Snapshot of the IPO
The IPO aimed to raise capital primarily for infrastructure development and operational enhancement.
IPO Fund Utilization Breakdown
- Total Funds Raised: ~₹59 Crore
- Price Band: ₹91 – ₹96 per share
- Minimum Lot Size: 1,200 shares
- Minimum Investment Required: ₹1.15 lakh
Use of Proceeds:
- Setting up manufacturing facilities for:
- Nutraceutical division
- Veterinary food division
- Machinery procurement for:
- Homecare segment
- Cosmetic division
- General corporate purposes
Summary of the Article
The Influx Healthtech share price listing on NSE Emerge impressed with a 38% gain over the IPO price, outperforming the market and grey market expectations. Backed by high investor demand—evident from a 187.32x subscription rate—the IPO successfully raised ₹59 Crore for expanding its production capabilities across multiple healthcare verticals. The company's future trajectory in the SME segment will be closely watched by investors tracking healthcare-focused opportunities.
Leave A Comment?